Sofinnova Partners Welcomes Mano Iyer as Venture Partner
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Manohar (Mano) Iyer, a serial entrepreneur with longstanding ties to Sofinnova, as Venture Partner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005045/en/
Mano Iyer (Photo: Business Wire)
Mr. Iyer will investigate global medical device investment opportunities across the Sofinnova Partners platform of strategies, with a particular focus on helping the firm’s in-house medtech accelerator, Sofinnova MD Start, incubate world-class companies.
Mr. Iyer has more than 25 years of experience in the medical device industry. In 2008, he was a founding member of the original MD Start team that incubated companies including CorWave and LimFlow. He also advised CoreValve, a Sofinnova Capital Strategy portfolio company, which was subsequently purchased by Medtronic for $800 million.
Mr. Iyer founded ReCor Medical during his time as an Entrepreneur-in-Residence at Sofinnova Partners in 2009. ReCor, another Sofinnova Partners investment, which is developing an ultrasound renal denervation system to treat high blood pressure, was successfully sold to Otsuka Medical Devices in 2018. Mr. Iyer left Sofinnova in 2013 to work full-time as the Chief Operating Officer of ReCor.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “We are delighted to have Mano back in the fold at Sofinnova Partners. He is an experienced company builder and a respected figure in the medical device community who has shown an uncanny ability to start successful companies no matter what condition the global economy is in.”
Anne Osdoit, Partner at Sofinnova Partners, said: “Mano joins us as MD Start is really hitting its stride. Several of our companies are maturing exceptionally well and we have a healthy flow of promising disruptive medtech projects. Mano brings a deep understanding of the sector thanks to his experience and network in the US and Europe. He also knows our medtech acceleration model inside out, having pioneered it with ReCor. We are thrilled to be working with him.”
Mr. Iyer said: “Sofinnova has realized something truly impressive in developing a first-class medtech ecosystem based out of Europe. The firm is recognized globally as an influential player in the space and I’m excited and proud to be back.”
Mr. Iyer started his career in medical devices as an engineer at Arrow International. While at Arrow, he met Tim Lenihan. In 2001, he co-founded Contract Medical International (CMI) with Mr. Lenihan, and ran operations and engineering. CMI specialized in the development and custom manufacturing of minimally invasive medical device systems. It was acquired by Heraeus Group in 2020.
After earning an MBA from Stanford, he joined Sofinnova Partners thanks to an introduction from Gerard Hascoët, whom he had also met while at Arrow. The trio (Hascoët, Lenihan, Iyer) joined forces with Antoine Papiernik and, with the backing of Sofinnova Partners, founded MD Start to create and incubate innovative medical device companies. Now in its third iteration, MD Start is fully integrated into the Sofinnova platform of strategies.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Head of Communications
+33 (0) 6 47 71 38 11
+1 212 223 0561
+33 (0) 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Enters Into Harbour Energy plc Trading Plan8.2.2023 17:00:00 EET | Press release
EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced that it has established a pre-arranged trading plan (the “Trading Plan”) to permit the sale of up to 2 million shares (the “Shares”) of Harbour Energy plc (HBR.L or the “Company”) held by certain controlled affiliates of EIG. As previously announced on July 8, 2022, EIG completed a distribution of the Shares to various EIG fund investors and EIG affiliated shareholders. The distributions were a taxable event for certain EIG affiliated shareholders and, as a result, EIG is undertaking a sale of the Shares pursuant to the Trading Plan primarily to cover such tax obligations. The Trading Plan, entered into on February 6, 2023, will permit Shares to be sold through March 9, 2023 at times that EIG might otherwise be precluded from doing so under insider trading laws or Harbour Energy plc trading restrictions. The Trading Plan will be administered by an independent broker and will be subjec
I Squared Capital establishes nLighten, a European edge datacenter platform8.2.2023 16:43:00 EET | Press release
I Squared Capital, through its ISQ Global Infrastructure Fund III, has established nLighten, an edge datacenter platform dedicated to delivering solutions for both traditional and low-latency use cases. I Squared has committed more than $500 million of equity to support nLighten’s ambition to bring high quality colocation services to underserved cities and regions across Europe. nLighten is part of I Squared Capital’s global datacenter portfolio, including KIO in the Americas and BDx in Asia. nLighten is led by former senior executives from Equinix, including Harro Beusker, Co-Founder and CEO, and Chad McCarthy, Co-Founder and CTO. Harro has held various leadership roles at Equinix, including SVP of Corporate Development for EMEA, Managing Director Germany and Netherlands and Interim Managing Director France, and Chad was most recently Equinix’s Global Head of Engineering Development and Master Planning. Both were instrumental in the development of Equinix’s business in EMEA as well as
Esri Releases New App to Easily View and Analyze Global Land-Cover Changes8.2.2023 16:00:00 EET | Press release
Land Use/Land Cover (LULC) maps are an increasingly important tool for decision-makers at local, regional, and national government levels around the world. These maps help inform policy and land management decisions around issues like sustainability, by contextualizing and quantifying the impacts of earth processes and human activity on the environment. Esri, the global leader in mapping and location intelligence, has now released a new online application, Sentinel-2 Land Cover Explorer. The app is structured around a web-based version of its own high-resolution global land-cover map, derived from European Space Agency (ESA) Sentinel-2 satellite imagery. The app is easy to access and leverages the same geographic information system (GIS) technology behind the land-cover map. The app, map, and source Sentinel-2 imagery are all part of the company's ArcGIS Living Atlas of the World. "GIS not only provides the capabilities necessary to produce and share data and maps such as LULC, it also
ThetaRay and Piie Collaborate in AI Technology for Insurance Payments8.2.2023 16:00:00 EET | Press release
ThetaRay, a leading provider of AI-powered transaction monitoring technology, and Piie, Inc., an insurtech providing an intelligent payment engine, today announced a collaboration to implement an advanced AML solution for insurance claim payments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005157/en/ Piie (Payments Intelligent Integration Engine) payments-as-a-service platform, including mobile application support. (Photo: Business Wire) Through the agreement, Piie (Payments Intelligent Integration Engine) will integrate ThetaRay’s AI-driven SONAR transaction monitoring AML solution to monitor and detect anomalies pointing to suspected financial crime on its payments-as-a-service platform that includes mobile application support. A scalable, secure payments platform headquartered in Charlotte, NC, Piie serves the insurance industry with an AI-driven real-time payments solution. Using ThetaRay’s transaction monitori
Novaliq Plans to File a Markting Authorisation Application for CyclASol® in the E.U. for the Treatment of Dry Eye Disease in July 20238.2.2023 16:00:00 EET | Press release
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) determined that CyclASol® is eligible to be reviewed in a centralized procedure to receive a Union Marketing Authorisation for the European Economic Area (EEA). In December 2022, EMA stated in its response that, based on the documentation provided by Novaliq, a submission is in the interest of patients at Community level under Article 3(2)b - Interest of patients of Regulation (EC) No 726/2004. Consequently, Novaliq has submitted a letter of intent to EMA to file the MAA in July 2023. Dry eye is one of the most
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom